Research data has shown that tamoxifen therapy prolonged both disease-free periods and also overall survival rates in patients with estrogen receptor (ER)-positive breast tumors, but had little benefit for patients who had ER-negative tumors. In addition, patients who were ER-negative, but progesterone receptor (PR)-positive, also improved with tamoxifen therapy.
